Clinical Trial Update: A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JS212 combination therapy for advanced esophageal squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• JS212

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING